NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Gastric Cancer
Ewing, NJ, April 7, 2021 – NovaRock Biotherapeutics Ltd announced today that their investigational new drug, NBL-015, a Claudin18.2 eADCC […]
Read More
NovaRock Biotherapeutics Announces Two E-Posters to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2021
Ewing, NJ, March 30, 2021 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]
Read More
NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases
Ewing, NJ, January 6, 2021 – NovaRock Biotherapeutics Ltd, announced today that the U.S. Food and Drug Administration (FDA) has […]
Read More
NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Pancreatic Cancer
Ewing, NJ, December 3, 2020 – NovaRock Biotherapeutics Ltd, announced today that their investigational new drug, NBL-015, has been granted […]
Read More
